+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry



Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry



Expert Opinion on Drug Safety 15(11): 1477-1482



Off-label or unlicensed use of psychotropic drugs is common rather than the exception in child and adolescent psychiatry. This use exposes patients to an unknown additional risk of ineffective or even harmful treatment. In addition, treatment with psychotropic drugs during a period of life when the patient undergoes marked developmental hormonal and neurobiological changes often requires different dosing regimes in later life and may result in adverse drug reactions, which are either not seen in adults at all or not in the same frequency. Areas covered: Given these critical safety issues, efficient pharmacovigilance methods as part of routine practice are essential for the improvement of patient care. The purpose of this article is to introduce methods to increase the safety of psychotropic drug use in youngsters. In particular, therapeutic drug monitoring (TDM) as a routine measure of proactive pharmacovigilance is discussed. Expert opinion: Given the special features of psychopharmacological therapy in children and adolescents in day-to-day clinical practise, proactive surveillance by using a close standardized 'patient monitoring' and long-term follow-up with TDM is very important. This approach could minimize the risk of exposing paediatric patients to ineffective treatments of uncertain or unknown risks.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059121493

Download citation: RISBibTeXText

PMID: 27551945

DOI: 10.1080/14740338.2016.1225721


Related references

Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44(6): 249-253, 2012

"Therapeutic drug monitoring", a strategy for improving drug safety in child and adolescent psychiatry and psychotherapy. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 33(3): 157-158, 2005

Therapeutic drug monitoring in child and adolescent psychiatry--practical recommendations. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 34(1): 5-13, 2006

Pharmacovigilance in psychiatry: pharmacogenetic tests and therapeutic drug monitoring are promising tools. Expert Review of Clinical Pharmacology 1(2): 183-185, 2008

Pharmacovigilance in child and adolescent psychiatry. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 43(1): 21-28, 2015

Clozapine in child and adolescent psychiatry Findings from drug monitoring over 10 years. Pharmacopsychiatry 26(5): 172, 1993

Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child and Adolescent Psychiatry and Mental Health 3(1): 14-14, 2009

Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. Journal of Child and Adolescent Psychopharmacology 16(3): 308-316, 2006

Reactive and proactive aggression in children--a review of theory, findings and the relevance for child and adolescent psychiatry. European Child & Adolescent Psychiatry 14(1): 11-19, 2005

The current status of lithium therapy in child and adolescent psychiatry. A report of the Committee on Biological Aspects of Child Psychiatry of the American Academy of Child Psychiatry, December 1977. Journal of the American Academy of Child Psychiatry 17(4): 717-720, 1978

Arctic co-operation in child and adolescent psychiatry. Proceedings from the VI Congress on Circumpolar Child and Adolescent Psychiatry. August 27-30, 1991, Kajaani, Finland. Arctic Medical Research 53 Suppl 1: 1-71, 1994

Therapeutic drug monitoring in epileptology and psychiatry FT "Therapeutic drug monitoring" in Epileptologie und Psychiatrie. 2008

To Andreas Warnke, Professor of Child and Adolescent Psychiatry, Head of the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University of Wuerzburg, Germany, to celebrate his professional life and work at the occasion of his 65th anniversary. Attention Deficit and Hyperactivity Disorders 2(4): 159-160, 2011

Child and adolescent psychiatry aspects of animal abuse (a comparison with aggressive patients in child and adolescent psychiatry). Schweizer Archiv für Neurologie und Psychiatrie 139(3): 59-67, 1988

Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry 44(6): 254-258, 2012